Prism Market View highlights EXOZ’ recent $2M NIH Phase IIB SBIR grant as a significant non-dilutive funding milestone that expands the company’s pharmaceutical pipeline beyond its NCT program and into rare cannabinoids and proprietary cannabinoid analogs.
The article notes that the two-year award validates eXoZymes’ AI-enhanced, cell-free biomanufacturing platform, which is designed to overcome the supply and purity challenges that have long constrained cannabinoid drug discovery, while positioning the company to develop novel pharmaceutical assets and pursue future licensing and strategic partnerships in a rapidly growing market.
Full story available on prismmarketview.com here